Credo Technology Earnings Preview: $600M optical revenue ramp in focus
BioLineRx disclosed its second-quarter 2026 financials, revealing flat revenue at $0.3 million and a widening net loss of $4.3 million. The company's lead drug, GLIX1, an oral small molecule for glioblastoma, showed promising safety data and expanding enrollment in early-stage trials at NYU Langone Health, Northwestern University, and Moffitt Cancer Center.
GLIX1's favorable profile includes no reliance on the immune system and a clean safety profile in animal studies. The company's cash position, $13.1 million, should cover operations through the first half of 2027, with a planned offering raising $3.75 million. Analysts suggest the stock may be undervalued at $2.675, with a fair value estimate exceeding the current price.
BioLineRx's focus on GLIX1, along with its financial challenges, will likely continue to drive investor interest.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
